Fosfomycun-trometamol
Phase 3Small molecule
Fosfomycun-trometamol is one of 37 small molecule programs targeting Urinary Tract Infection. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Merrem
BB. Braun Medical Inc.
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Comparator: Pbo
Merck & Co.Phase 3
Prulifloxacin
Merck & Co.Phase 3
Piperacillin/tazobactam
PfizerPhase 3
Amoxicillin/clavulanate Potassium
Johnson & JohnsonPhase 3
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
Imipenem+cilastatin/relebactam
Merck & Co.Phase 3
Amoxicillin/clavulanate
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fosfomycun-trometamol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Rouen